Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTLD-2 trial
DRKS00005380Phase 2Completed
- Sponsor
- DIAKO
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by DIAKO. Started Nov 2014; status: completed.
02
Drugs
rituximab
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on DRKS00005380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00005380.